Integra LifeSciences Posts Street Beating Earnings, Backs FY22 Guidance

  • Integra LifeSciences Holdings Corp IART reported Q1 FY22 sales of $376.6 million, +4.6% Y/Y on a reported basis and 5.6% organic, beating the consensus of $362.04 million.
  • Adjusted EPS stood at $0.74, ahead of The Street estimate of $0.68.
  • Integra Lifesciences in Q1 also announced the launch of its NeuraGen 3D nerve guide matrix, a resorbable implant to repair peripheral nerve discontinuities. 
  • The Company says the NeuraGen 3D is the only nerve repair product specifically engineered to create an optimized environment for mid-gap nerve regeneration, compared with hollow nerve conduits alone.
  • The adjusted gross margin was 67.7%, compared to 67.3% in the prior year.
  • Guidance: Integra Lifescience expects Q2 FY22 sales of $392 million - $400 million, compared to the consensus of $394.32 million.
  • Adjusted EPS is expected to be 0.78 - $0.82, versus The Street estimate of $0.80.
  • For FY22, the Company raised its organic growth expectations from 3.5% - 5% to 3.8% - 5.2%, reflecting better-than-expected Q1 performance and the current uncertainty in global markets and continuing supply constraints. 
  • FY22 sales and EPS guidance remain unchanged at $1.58 billion - $1.6 billion (consensus of $1.59 billion) and $3.27 - $3.35 (consensus of $3.31), respectively.
  • Price Action: IART shares are up 3.23% at $62.57 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!